



 **International  
Myeloma Society**

# PROGRAMS & INITIATIVES





## Vision Statement

To cure myeloma by fostering research, education and excellence in clinical care worldwide.

## Mission Statement

The International Myeloma Society (IMS) promotes education, research and clinical care globally by:


- Building a global myeloma community
- Educating for today and the future
- Fostering clinical and translational research in myeloma
- Assuring clinical excellence worldwide



## Our Membership

The International Myeloma Society has members in 54 countries. All Physicians and Researchers with an interest in myeloma are invited to become members.

Trainees can apply to be members-in-training at a special rate. Industry representatives and allied health professionals are welcome to become associate members.



## Membership Benefits

You are invited to become a member of the International Myeloma Society. IMS membership entitles each individual to sponsor one abstract to each IMS Meeting. Other membership privileges and benefits include:

- Sponsor abstract at the IMS Annual Meeting
- A copy of the abstract and education book produced for the International Myeloma Workshop
- Discounted registration fees at the IMS Annual Meeting and other IMS sponsored events
- Free online subscription to the journal Clinical Lymphoma, Myeloma & Leukemia
- An effective voice for myeloma advocacy
- Eligible to be a candidate for Board of Directors, Subcommittees, Awards, Travel Grants, Host the IMW
- Nomination and election process
- Access to the slides from the Annual Meeting and other myeloma meetings

# Our Leadership



**Philippe Moreau**  
*President*



**Shaji Kumar**  
*Vice President*



**Noopur Raje**  
*Secretary*




**María-Victoria Mateos**  
*Treasurer*



**Nikhil Munshi**  
*Immediate Past President*



**Jesús San Miguel**  
*Past President*



**Kenneth Anderson**  
*Past President*



# Board Members



**Masahiro Abe**



**Dorotea Fantl**



**Francesca Gay**



**Sundar Jagannath**



**Pankaj Malhotra**



**Saad Usmani**



**Elena Zamagni**

# EDUCATIONAL PROGRAMS

## IMS Annual Meeting

The International Myeloma Society Annual Meeting is the leading annual meeting in myeloma, focusing on basic, preclinical, and clinical aspects of multiple myeloma and related plasma cell disorders.

The IMS Annual Meetings feature presentations from more than 150 key opinion leaders who serve as members of our faculty. Abstracts, posters, joint symposia, keynotes, meet the expert sessions, career development workshops, roundtable discussions and more are offered each year.






Future editions of the meeting have been scheduled:

- 21st Annual Meeting Rio de Janeiro, Brazil September 25-28, 2024.
- 22nd Annual Meeting: Toronto, Canada September 18-21, 2025
- 23rd Annual Meeting: Glasgow, Scotland September 23-26, 2026

## Attendance Data



\*In-person + virtual attendees

## Activities

One of the most important goals of IMS is to provide clinically focused education to practicing oncologists worldwide. The IMS accomplishes this mission by providing educational forums in the form of workshops conducted around the globe.



The goal for the Educational Workshop is to share with local hematologists state-of-the-art methods in diagnosis, monitoring and treatment of plasma cell malignancies paying special attention to the current practice in the local countries and the opportunities for improvement. We also offer the opportunity to establish potential collaborations with the invited speakers including the possibility of visiting local institutions or establishing fellowship programs.

The program includes lectures plus roundtable discussions around the most hot and controversial topics and case presentations to supplement didactic education. The format of the roundtable also includes the counterpoint opinion of the invited speakers with the local hematologists based on both challenging questions and clinical cases. Past programs have taken place throughout the world in countries including the United States, Chile, Greece, Brazil, Spain, Germany, and the Czech Republic.


### Upcoming Programs:

- Novel Immune Therapies in Multiple Myeloma Educational Workshop – Hamburg, Germany – October 16, 2023
- Novel Immune Therapies in Multiple Myeloma Educational Webinars – March 27, 2024 and May 15, 2024
- Educational Workshop – Buenos Aires, Argentina – April 19-20, 2024
- Educational Workshop – South Africa – January 2025



## Workshop on Immune Effector Cell Therapies in Multiple Myeloma

Since 2019, the International Myeloma Society hosts an annual Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss various immune-based therapies in myeloma including CAR T cell clinical data and promising preclinical leads, review the latest correlative analyses exploring predictors of response and resistance mechanisms, evaluate uniform practices in managing patients with CRS and other complications, and discuss next-generation cell therapy strategies, including “off-the-shelf” allogeneic and NK-cell based approaches. This year we also included a session on cell-engaging bispecific antibody-based approaches.




The next Immune Effector Cell Therapies Workshop is scheduled for March 23-24, 2024 in Boston, Massachusetts.



## Workshop on Genomics – Defining high-risk disease and developing targeted therapies

The IMS recently hosted the first of a planned series of annual meetings on Genomics. This two-day meeting will take place in Europe and will be co-hosted by key thought leaders in Genomics from the United States, Spain and France. The initial invitation-only meeting was focused on the redefinition of high-risk myeloma and will result in a white paper of recommendations. The meeting touched on the latest research in the following areas: risk features, hyperdiploidy, incorporation of other platforms, targeted drugs, single-cell technology, micro-environmental impact of genomic subtype, myeloma heterogeneity, and genomic and transcriptomic changes driving drug resistance, chromatin structure and non-coding RNA.



The second Workshop on Genomics will be held in July 2024 in Europe.

## Collaborations with local societies

The IMS co-sponsors meetings and workshops organized by local myeloma societies around the world. The IMS provides insights for programs, speaker suggestions and educational content for these meetings to ensure content is free from conflict and bias. These workshops foster local participation while providing an international view on recent developments. IMS has co-sponsored meetings and symposia with local organizations in Poland, Israel, Japan and Argentina as well as with larger groups including IFM, EHA, COMy and DGHO with future collaborations being planned.

## Supporting Trainees

IMS believes that supporting trainees assures the future of myeloma treatment. The Society has a designated Career Development subcommittee, focused entirely on how the IMS can support postdoctoral fellows, trainees and other young investigators. The Career Development Award has provided over \$1.2 million in funding for 19 young investigators to spend a year working in a lab in a different country, resulting in collaborations between 31 institutions in 14 different countries.

IMS also hosts special workshops for postdoctoral fellows at the annual meeting, as well as sessions in our other workshops throughout the year.

Through the Young Investigator Awards, the International Myeloma Society provides travel grants to young myeloma researchers to assist with expenses relating to their participation at the Annual Meeting. Since 2019, the IMS has provided awards to over 160 young investigators.



# RESEARCH INITIATIVES

## *Funding Opportunities*

### International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Award

PAULA &  
RODGER RINEY  
FOUNDATION

**Goal:** To foster and support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of plasma cell disorders. Although focused on finding a cure for multiple myeloma, the area of research is broad. This award will also encourage interaction between institutions to enhance collaborative research.

**Budget:** The grant will be an award between \$175,000 to \$250,000.

**Research areas:** Translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. The Translational Research is defined in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the treatment of myeloma. The translational research projects may involve the use of any cellular, molecular, structural, biochemical, and/or genetic experimental approaches. By this definition, projects





**Paula and Rodger Riney**

are permitted to move not only in the forward direction, toward clinical trials and studies in areas of prevention, early detection, treatment, and development of biomarkers, but also in the reverse direction, using human biospecimens, often from clinical trials, to study new phenomena, or to develop new targets and treatments based on results from human studies. The project must be focused on translational research that meets the definition provided above and results in clinical translation. The project must be dedicated to capitalizing on research opportunities that have the potential to change the current paradigm in the management of myeloma.


## Career Development Award

**Goal:** To foster the development of an academic career for young scientists pursuing research in the field of plasma cell disorders and to promote the development of the next generation of leaders in this field. This award will also encourage interaction between institutions to enhance collaborative research.



**Budget:** The grant will be an award of up to \$75,000 including the maximal allowable institutional overhead of 8%. This may include 1 year of salary support for the grantee, budget for visa status adjustment and travel allowance.

**Research areas:** Basic and translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. Outcomes research and non-laboratory projects that do not require a stay abroad in a research laboratory do not qualify for full funding but may be considered to receive partial funding.





## International Myeloma Study Summits

The role of the International Myeloma Society is to help facilitate conversation and discussion and, wherever possible, collaboration. Within a short time, there has been great progress in multiple myeloma with several newer agents and triplet - and quadruplet- combinations. There has been significant progress in understanding the role of MRD and evaluating various other endpoints. This has led to the development of multiple clinical studies, contributing tremendous amounts of data to the field. However, it has also become clear that there are significant numbers of ongoing and planned studies, of which many may not be aware.

In response to this issue, the IMS has created the International Myeloma Study Summit, a twice yearly gathering of leaders from large myeloma groups throughout the world. This meeting serves as an opportunity for group leaders to share the details of ongoing Phase III studies and plans, within the limits of what can be shared, so that other groups can learn from and develop their future studies to complement ongoing research without overlapping.

# ADVOCACY

## *To Stimulate Awareness and Access*

### Therapeutic MAP (TMAP)

The International Myeloma Society is focused on providing global support and educational tools to help oncologists and hematologists with treatment decisions for myeloma patients. Treatment for multiple myeloma has evolved very rapidly over the last several years with a significant improvement in outcomes. However, the access and availability of drugs remain variable and dictated by regional approval and reimbursement strategies. Consequently, practice patterns are variable and patient access is unequal. Given the rapidly accumulating data and available options, treatment decisions are not straightforward. To combat

Available Regimen	
	Drug Combinations
Newly Diganosed MM	VRD,VTD,VCD, VTD-dara, Rd, Rd-dara, VMP, VMP-dara
First Relapse	rd-dara,lxa-Rd, KRD, KD-dara, PVD, Kd, Vd, Vd-dara
Relapse: 1-3 lines	Rd-dara, lxa-Rd, KRD, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD
Relapse: ≥ 3 lines	Rd-dara, lxa-Rd, KRD, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD
Relapse: ≥ 4 lines	Rd-dara, lxa-Rd, KRD, KD-dara, PVD, Kd, Vd, Vd-dara, PD, PCD, Isa-PD
Other	



this disparity, the IMS has started the Therapeutic Map (TMAP) initiative. TMAP will be a computer-based program that will provide region/country-specific guidelines to help hematologist/ oncologists in the care of multiple myeloma patients, by providing the user with availability and coverage information in each region or country. The TMAP steering committee includes 16 leaders in myeloma from nine countries.

Data is currently being collected for select countries and efforts in programming the map are underway. It is expected to launch in late 2023.

Available Agents

	Drug Combinations
Newly Diganosed MM	Bortezomib, lenalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab
First Relapse	Bortezomib, carfilzomib, , lenalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: 1-3 lines	Bortezomib, carfilzomib, ixazomib, lenalidomide, pomalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: ≥ 3 lines	Bortezomib, carfilzomib, ixazomib, lenalidomide, pomalidomide, dexamathasone, melphalan, thalidomide, cyclophosphamide, daratumumab, isatuximab
Relapse: ≥ 4 lines	Belatamab, selinexor, melflufen, idecel
Other	

## Regulatory Relationships

The outcomes for patients with multiple myeloma have improved with the introduction of new therapies and approaches to care. However, relapses are common and multiple myeloma remains a difficult disease to treat at that point so the need for new therapies remains. Recent trial results and developments in the field of multiple myeloma necessitate a discussion of the current paradigm to identify opportunities to facilitate future drug development of novel therapies in multiple myeloma and improve patient outcomes.

On November 8-9, 2022, the IMS hosted a joint symposium with the FDA, which provided a forum for open discussion among academia, industry and regulatory agencies about clinical drug development in multiple myeloma. This workshop focused on discussions surrounding trial design, patient population, and endpoints in the different multiple myeloma disease settings with an aim to advance the future of drug development in multiple myeloma. This meeting served to engage stakeholders to discuss opportunities and challenges in designing trials applicable to the US patient population. A manuscript from the meeting discussion has been developed for publication.

A similar interaction with EMA is under discussion.

### Upcoming FDA/IMS Joint Program

Defining Patient Populations for Clinical Studies in MM

February 22-23, 2024

Hyatt Regency Bethesda

Bethesda, MD

## IMS/EMA Collaborative Initiative

In progress

# IMS AWARDS



## Waldenström Lifetime Achievement Award

Named for Jan Waldenström, a pioneer in treating blood cancers, the Waldenström Lifetime Achievement Award has been given by the IMS at each International Myeloma Workshop since 1989. This award is given to outstanding researchers in recognition of their long term contributions to the myeloma field.

### Past Recipients

- 1989 – D. Bergsagel
- 1991 – R. Kyle
- 1993 – S. Salmon
- 1995 – M. Potter
- 1997 – R. Alexanian
- 1999 – B. Barlogie
- 2001 – H. Mellstedt
- 2003 – K. Anderson
- 2005 – J-L Harousseau
- 2007 – J. San Miguel
- 2009 – B. Durie
- 2011 – W. M. Kuehl
- 2013 – N. Munshi
- 2015 – M. Attal
- 2017 – M. A. Dimopoulos
- 2019 – G. Merlini
- 2021 – S. V. Rajkumar
- 2022 – P. Sonneveld
- 2023 – S. Jagannath



## The Bart Barlogie Clinical Investigator Award

In recognition of the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors established the Bart Barlogie Clinical Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research.

The Bart Barlogie Clinical Investigator Award will be given to an investigator in recognition of their research in the myeloma field.

### Past Recipients

- 2015 – B. Paiva
- 2017- G. Palladini
- 2019 – F. Gay
- 2021 – S. Usmani
- 2022 – M-V. Mateos
- 2023 – S. Kumar





## Ken Anderson Basic and Translational Research Award

Established by IMS to honor the seminal contributions of Professor Ken Anderson for his bench to bedside translational research. The Ken Anderson Basic and Translational Research Award will be given to an investigator to recognize excellence in translational research in myeloma

### Past Recipients

- 2017 – I. Ghobrial
- 2019 – C. Mitsiades
- 2021 – E. P. Neri
- 2022 – N. Raje
- 2023 – H. Avet-Loiseau



*Coming Soon:*

**ARTEMIS**

by the International Myeloma Society

Analytic Research and daTa Exchange  
for Myeloma International Studies

**Computational Biology Training Program**

**Digital Data Hub**



[www.myelomasociety.org](http://www.myelomasociety.org)